DK2895509T3 - T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3 - Google Patents

T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3 Download PDF

Info

Publication number: DK2895509T3
Authority: DK; Denmark
Prior art keywords: mage; limited; mhc class; cell receptors; receptors recognizing
Prior art date: 2012-09-14

Application number

DK13767200.2T

Other languages

English (en)

Inventor

Paul F Robbins

Steven A Rosenberg

Xin Yao

Original Assignee

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-14

Filing date

2013-09-13

Publication date

2020-03-09

2013-09-13 Application filed by Us Health filed Critical Us Health

2020-03-09 Application granted granted Critical

2020-03-09 Publication of DK2895509T3 publication Critical patent/DK2895509T3/da

Links

SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 title 1
108091008874 T cell receptors Proteins 0.000 title 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Mycology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Hospice & Palliative Care (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)

DK13767200.2T 2012-09-14 2013-09-13 T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3 DK2895509T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261701056P	2012-09-14	2012-09-14
PCT/US2013/059608 WO2014043441A1 (en)	2012-09-14	2013-09-13	T cell receptors recognizing mhc class ii-restricted mage-a3

Publications (1)

Publication Number	Publication Date
DK2895509T3 true DK2895509T3 (da)	2020-03-09

Family

ID=49253425

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19212016.0T DK3636665T3 (da)	2012-09-14	2013-09-13	T-cellereceptorer, som genkender mhc klasse ii-begrænset mage-a3
DK13767200.2T DK2895509T3 (da)	2012-09-14	2013-09-13	T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK19212016.0T DK3636665T3 (da)	2012-09-14	2013-09-13	T-cellereceptorer, som genkender mhc klasse ii-begrænset mage-a3

Country Status (19)

Country	Link
US (4)	US9879065B2 (da)
EP (3)	EP2895509B1 (da)
JP (4)	JP6461796B2 (da)
KR (4)	KR102370307B1 (da)
CN (2)	CN113754755A (da)
AU (4)	AU2013315391B2 (da)
CA (1)	CA2884743C (da)
CY (1)	CY1122720T1 (da)
DK (2)	DK3636665T3 (da)
ES (2)	ES2925307T3 (da)
HR (1)	HRP20200325T1 (da)
HU (1)	HUE048014T2 (da)
IL (3)	IL286786B (da)
LT (1)	LT2895509T (da)
MX (2)	MX367279B (da)
PL (1)	PL2895509T3 (da)
PT (1)	PT2895509T (da)
SI (1)	SI2895509T1 (da)
WO (1)	WO2014043441A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6599450B2 (ja)	2014-10-02	2019-10-30	アメリカ合衆国	がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
CN107074932A (zh) *	2014-10-02	2017-08-18	美国卫生和人力服务部	分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
KR20220167337A (ko) *	2015-03-27	2022-12-20	이매틱스 바이오테크놀로지스 게엠베하	다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
GB201515321D0 (en) *	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017070042A1 (en)	2015-10-20	2017-04-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods of producing t cell populations using akt inhibitors
WO2017139199A1 (en)	2016-02-10	2017-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inducible arginase
US11208468B2 (en)	2016-02-18	2021-12-28	The Wistar Institute Of Anatomy And Biology	Methods and compositions for treating melanoma
EP4177264A1 (en) *	2016-03-16	2023-05-10	Immatics Biotechnologies GmbH	Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604494D0 (en) *	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
CN106749620B (zh) *	2016-03-29	2020-09-25	广东香雪精准医疗技术有限公司	识别mage-a1抗原短肽的t细胞受体
US10188749B2 (en)	2016-04-14	2019-01-29	Fred Hutchinson Cancer Research Center	Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018097951A1 (en)	2016-11-22	2018-05-31	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-mage-a3/a6 antibodies
DE102016123859B3 (de)	2016-12-08	2018-03-01	Immatics Biotechnologies Gmbh	Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN108250289B (zh) *	2016-12-28	2021-10-08	香雪生命科学技术（广东）有限公司	源自于mage b6的肿瘤抗原短肽
CN110121336A (zh)	2017-01-05	2019-08-13	弗莱德哈钦森癌症研究中心	改善疫苗功效的系统和方法
US11649288B2 (en)	2017-02-07	2023-05-16	Seattle Children's Hospital	Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
JP7178355B2 (ja)	2017-02-28	2022-11-25	エンドサイト・インコーポレイテッド	Ｃａｒｔ細胞療法のための組成物および方法
WO2019070435A1 (en) *	2017-10-05	2019-04-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	METHODS FOR SELECTIVE EXPANSION OF CELLS EXPRESSING A TCR WITH A CONSTANT MURINE REGION
US20200316122A1 (en)	2017-10-11	2020-10-08	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Methods of producing t cell populations using p38 mapk inhibitors
CN109776671B (zh) *	2017-11-14	2022-05-27	杭州康万达医药科技有限公司	分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CN109837248A (zh) *	2017-11-25	2019-06-04	深圳宾德生物技术有限公司	一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用
CN109836490A (zh) *	2017-11-25	2019-06-04	深圳宾德生物技术有限公司	一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
CN112292138A (zh)	2018-01-22	2021-01-29	西雅图儿童医院（Dba西雅图儿童研究所）	Car t细胞的使用方法
EP3749770A1 (en)	2018-02-09	2020-12-16	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Tethered interleukin-15 and interleukin-21
CN112236447B (zh) *	2018-04-19	2023-10-20	得克萨斯州大学系统董事会	具有mage-b2特异性的t细胞受体及其用途
US20210071141A1 (en)	2018-04-24	2021-03-11	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
EP3714941A1 (en) *	2019-03-27	2020-09-30	Medigene Immunotherapies GmbH	Mage-a4 tcrs
WO2021011482A1 (en) *	2019-07-15	2021-01-21	Neogene Therapeutics B.V.	Method to isolate tcr genes
DE102019121007A1 (de)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Antigenbindende Proteine, die spezifisch an MAGE-A binden
JP2020143057A (ja) *	2020-04-01	2020-09-10	アメリカ合衆国	がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
CN116583537A (zh)	2020-09-08	2023-08-11	美国卫生和人力服务部	与对过继细胞疗法的应答相关的t细胞表型
EP4243937A2 (en)	2020-11-13	2023-09-20	The United States of America, as represented by the Secretary, Department of Health and Human Services	Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
EP4456911A2 (en)	2021-12-31	2024-11-06	The United States of America, as represented by the Secretary, Department of Health and Human Services	T cell therapy with vaccination as a combination immunotherapy against cancer
CN117946245B (zh) *	2023-02-23	2024-08-02	暨南大学	一种识别mage-a3抗原短肽的t细胞受体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
IN165717B (da)	1986-08-07	1989-12-23	Battelle Memorial Institute
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
JP3266311B2 (ja)	1991-05-02	2002-03-18	生化学工業株式会社	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
AU2001236892A1 (en)	2000-02-08	2001-08-20	The Penn State Research Foundation	Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2012013913A1 (en) *	2010-07-28	2012-02-02	Immunocore Ltd	T cell receptors
PT2618835T (pt) *	2010-09-20	2017-08-08	Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz	Epítopos de célula t e recetores de célula t específicos de antigénio
WO2012054825A1 (en) *	2010-10-22	2012-04-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-mage-a3 t cell receptors and related materials and methods of use
CN102251033B (zh) *	2011-07-05	2013-03-20	北京大学人民医院	基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
SI2755997T1 (sl)	2011-09-15	2018-11-30	The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health	T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
US9413985B2 (en) *	2012-09-12	2016-08-09	Lattice Semiconductor Corporation	Combining video and audio streams utilizing pixel repetition bandwidth

2013
- 2013-09-13 KR KR1020217029207A patent/KR102370307B1/ko active IP Right Grant
- 2013-09-13 IL IL286786A patent/IL286786B/en unknown
- 2013-09-13 MX MX2015003061A patent/MX367279B/es active IP Right Grant
- 2013-09-13 KR KR1020207028713A patent/KR102303166B1/ko active IP Right Grant
- 2013-09-13 JP JP2015532065A patent/JP6461796B2/ja active Active
- 2013-09-13 EP EP13767200.2A patent/EP2895509B1/en active Active
- 2013-09-13 US US14/427,671 patent/US9879065B2/en active Active
- 2013-09-13 WO PCT/US2013/059608 patent/WO2014043441A1/en active Application Filing
- 2013-09-13 DK DK19212016.0T patent/DK3636665T3/da active
- 2013-09-13 AU AU2013315391A patent/AU2013315391B2/en active Active
- 2013-09-13 CN CN202111028896.0A patent/CN113754755A/zh active Pending
- 2013-09-13 PT PT137672002T patent/PT2895509T/pt unknown
- 2013-09-13 ES ES19212016T patent/ES2925307T3/es active Active
- 2013-09-13 EP EP19212016.0A patent/EP3636665B1/en active Active
- 2013-09-13 KR KR1020157006543A patent/KR102165350B1/ko active IP Right Grant
- 2013-09-13 HU HUE13767200A patent/HUE048014T2/hu unknown
- 2013-09-13 EP EP22174521.9A patent/EP4159753A1/en active Pending
- 2013-09-13 CA CA2884743A patent/CA2884743C/en active Active
- 2013-09-13 ES ES13767200T patent/ES2774931T3/es active Active
- 2013-09-13 SI SI201331678T patent/SI2895509T1/sl unknown
- 2013-09-13 DK DK13767200.2T patent/DK2895509T3/da active
- 2013-09-13 LT LTEP13767200.2T patent/LT2895509T/lt unknown
- 2013-09-13 CN CN201380059102.4A patent/CN104968675B/zh active Active
- 2013-09-13 PL PL13767200T patent/PL2895509T3/pl unknown
- 2013-09-13 KR KR1020227006700A patent/KR102480188B1/ko active IP Right Grant
2015
- 2015-03-04 IL IL237560A patent/IL237560B/en active IP Right Grant
- 2015-03-10 MX MX2019009641A patent/MX2019009641A/es unknown
2017
- 2017-08-23 AU AU2017219019A patent/AU2017219019B2/en active Active
- 2017-12-20 US US15/848,344 patent/US10611815B2/en active Active
2018
- 2018-12-26 JP JP2018243703A patent/JP6728326B2/ja active Active
2019
- 2019-08-06 AU AU2019213329A patent/AU2019213329B2/en active Active
2020
- 2020-02-26 HR HRP20200325TT patent/HRP20200325T1/hr unknown
- 2020-03-03 CY CY20201100190T patent/CY1122720T1/el unknown
- 2020-03-09 US US16/812,845 patent/US20200270329A1/en not_active Abandoned
- 2020-04-16 IL IL274003A patent/IL274003B/en unknown
- 2020-07-01 JP JP2020114090A patent/JP6923714B2/ja active Active
2021
- 2021-06-07 AU AU2021203746A patent/AU2021203746B2/en active Active
- 2021-07-29 JP JP2021124003A patent/JP7270001B2/ja active Active
2022
- 2022-09-28 US US17/936,006 patent/US20230089465A1/en active Pending

Also Published As

Publication number	Publication date
US10611815B2 (en)	2020-04-07
EP3636665B1 (en)	2022-06-29
CA2884743C (en)	2023-03-14
IL286786B (en)	2022-09-01
CN104968675B (zh)	2021-09-24
KR20210114563A (ko)	2021-09-23
AU2013315391B2 (en)	2017-06-08
WO2014043441A1 (en)	2014-03-20
AU2017219019A1 (en)	2017-09-14
AU2021203746A1 (en)	2021-07-01
JP2020178702A (ja)	2020-11-05
HRP20200325T1 (hr)	2020-06-12
JP6923714B2 (ja)	2021-08-25
SI2895509T1 (sl)	2020-04-30
JP2015535816A (ja)	2015-12-17
LT2895509T (lt)	2020-03-25
EP3636665A1 (en)	2020-04-15
KR20220031941A (ko)	2022-03-14
MX367279B (es)	2019-08-13
KR20200118248A (ko)	2020-10-14
ES2925307T3 (es)	2022-10-14
KR102165350B1 (ko)	2020-10-14
EP4159753A1 (en)	2023-04-05
IL274003B (en)	2021-10-31
KR102370307B1 (ko)	2022-03-04
EP2895509B1 (en)	2019-12-04
AU2013315391A1 (en)	2015-04-02
CY1122720T1 (el)	2021-03-12
JP7270001B2 (ja)	2023-05-09
JP2019088286A (ja)	2019-06-13
MX2015003061A (es)	2015-11-06
CN104968675A (zh)	2015-10-07
AU2019213329B2 (en)	2021-03-11
JP2021191265A (ja)	2021-12-16
CN113754755A (zh)	2021-12-07
IL286786A (en)	2021-10-31
IL274003A (en)	2020-05-31
US20230089465A1 (en)	2023-03-23
AU2017219019B2 (en)	2019-05-09
US20150246959A1 (en)	2015-09-03
KR102480188B1 (ko)	2022-12-21
US9879065B2 (en)	2018-01-30
ES2774931T3 (es)	2020-07-23
MX2019009641A (es)	2019-11-28
US20180127479A1 (en)	2018-05-10
PT2895509T (pt)	2020-03-13
IL237560A0 (en)	2015-04-30
IL237560B (en)	2020-05-31
AU2019213329A1 (en)	2019-08-29
KR20150052086A (ko)	2015-05-13
HUE048014T2 (hu)	2020-05-28
KR102303166B1 (ko)	2021-09-17
CA2884743A1 (en)	2014-03-20
EP2895509A1 (en)	2015-07-22
US20200270329A1 (en)	2020-08-27
AU2021203746B2 (en)	2024-05-02
JP6728326B2 (ja)	2020-07-22
PL2895509T3 (pl)	2020-07-27
JP6461796B2 (ja)	2019-01-30
DK3636665T3 (da)	2022-10-03

Publication	Publication Date	Title
DK2895509T3 (da)	2020-03-09	T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3
DK3024468T3 (da)	2019-07-22	T-cellereceptorer
IL236792A0 (en)	2015-03-31	Engineering of t-cell receptors
DK3424947T3 (da)	2021-02-22	Genmodificerede t-celle-receptor-mus
FR2987609B1 (fr)	2015-07-24	Moyens antiaffaissement
BR302012003701S1 (pt)	2014-05-27	Configuração aplicada a um dispositivo de comunicação.
DK3336866T3 (da)	2021-01-25	Optoelektronisk anordning
BR112015002958A2 (pt)	2017-08-08	aparelho de posicionamento de paciente articulado.
BR112014033077A2 (pt)	2017-08-01	combinação de vacina.
DK3187586T3 (da)	2019-10-14	Inducerbar co-ekspressionssystem
DK2910604T3 (da)	2022-05-16	Højdielektrisk film
IT1398416B1 (it)	2013-02-22	Dispositivo elettrovalvolare.
CO6910195A2 (es)	2014-03-31	Moduladores selectivos del receptor andrógeno
FI20125972A (fi)	2014-03-21	Sovitin
FR2986872B1 (fr)	2014-03-07	.
IT1399382B1 (it)	2013-04-16	Dispositivo.
BR112014027645A2 (pt)	2018-04-10	5-halogenopirazol bifenilcarboxamidas.
BR112015009171A2 (pt)	2017-07-04	conjunto de cabeça de poço
FR3000112B1 (fr)	2015-03-06	Structure de securite.
FR2997152B1 (fr)	2015-01-02	Support pneumatique.
BR302012005282S1 (pt)	2013-10-08	Configuração aplicada a um gatilho dispensador de adesivo.
EE201300020A (et)	2013-08-15	Laskumisseadeldis
ES1076472Y (es)	2012-06-08	Abridores para latas de anillas
ES1077677Y (es)	2013-02-21	Dispositivo receptor de excretas
FR2998032B1 (fr)	2018-08-31	Lanterne